Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the rapidity and durability of response, in the JAKARTA1 (NCT01437787) and JAKARTA2 (NCT01523171) studies evaluating fedratinib in patients with intermediate or high-risk myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
